Merck Tests Molnupiravir, an Investigational Product, at the Lung Center of the Philippines While Large Ivermectin Trial Runs in Parallel

Merck Tests Molnupiravir, an Investigational Product at the Lung Center of the Philippines While Large Ivermectin Trial Runs in Parallel

While the Philippines recently announced a large national ivermectin trial targeting early-onset COVID-19, another commercial study seeks to accelerate sufficient safety and efficacy data in that Southeast Asian nation as well, as Merck recently kicked off a Phase 3 trial there testing the oral antiviral drug Molnupiravir, led by the Lung Center of the Philippines. Although Merck developed a version of ivermectin that’s been used to safely quell parasitic-born illness in many tropical areas for four decades, the company went on the offensive against its own product’s use as a therapy for the COVID-19 indication. So now the American pharmaceutical company is in a race against time and its own generic product to carve out market share as what has been a great American pharmaceutical company and Ridgeback Biotherapeutics LP came together to commercialize the drug initially discovered at Emory University. They compete potentially against Roche and Pfizer but also other drug companies developing oral antiviral treatments for COVID, such as ivermectin. According to local media, the Lung Center of the Philippines seeks participants for the study as it has only thus far enrolled a couple ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee